Clear 8°. Wind Chill: -6°. Wind: SW 9 mph.
Loading advertisement…
Trending: ‘Severe’ geomagnetic storm could make northern lights visible in southern US
HomeNewsNationalHealth ( Page 69)

Health

Subscribe to the Health News Feed.
SHARE NOW
by

Hims and Hers beats revenue estimates on strong subscriber growth

By Kamal Choudhury and Amina Niasse (Reuters) -Hims and Hers Health beat Wall Street estimates for third-quarter revenue on Monday, as the telehealth company added subscribers and expanded its personalized healthcare offerings. The company and rivals have launched programs that offer “personalized” versions of semaglutide, ...
by

Vertex beats quarterly estimates on cystic fibrosis demand, new drugs

(Reuters) -Vertex Pharmaceuticals reported on Monday that it beat Wall Street estimates for third-quarter results, driven by strong demand for its cystic fibrosis treatments and early contributions from newer medicines. The Boston-based company reported total revenue of $3.08 billion for the quarter ended September 30, ...
by

Sarepta’s Duchenne gene therapy misses main goal in late-stage study; shares fall

(Reuters) -Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal, sending its shares plummeting 21% in extended trading. The study tested casimersen and golodirsen in 225 boys aged 6 to 13 ...
by

WATCH: Amid criticism, Pritzker defends using expletive to tell Trump where to go

(The Center Square) – Illinois Gov. J.B. Pritzker on Monday defended the use of an expletive that he used in front of a teachers union directing President Donald Trump and supporters where to go. ...
by

AstraZeneca wins shareholder backing for NYSE listing in US pivot

(Reuters) -AstraZeneca shareholders approved a direct listing of the drugmaker’s shares on the New York Stock Exchange on Monday, giving it access to a deeper capital pool. The drugmaker said 99.36% of votes cast in a general meeting favoured the proposal. The company needed at ...
by

Novo Nordisk says Metsera bid won’t raise antitrust issues

COPENHAGEN (Reuters) -Denmark’s Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues. Novo Nordisk last week launched a rival bid for obesity biotech Metsera, exceeding an offer from Pfizer as the drugmakers ...
Loading advertisement…
by

Appeals court: IT firm can’t make insurer foot bill for $28M face scan deal

A state appeals panel has agreed an insurance company doesn’t need to contribute to a $28.5 million settlement that resolved a class action accusing an information technology firm of violating a biometrics privacy law for its part in a Chicago Police Department facial scan ...
by

Pfizer files second lawsuit against Metsera, Novo Nordisk

(Reuters) -Pfizer Inc said on Monday it has filed a second lawsuit against its controlling shareholder, Metsera, and Novo Nordisk in a Delaware federal court, accusing them of anticompetitive conduct. The latest lawsuit follows Danish drugmaker Novo’s bold and unsolicited counter-bid for U.S.-based Metsera, surprising ...
by

Tylenol maker Kenvue misses sales estimates amid Kimberly-Clark’s $48.7-billion deal

(Reuters) -Kenvue missed Wall Street estimates for third-quarter sales on Monday, while it also announced its acquisition by Kimberly-Clark for about $48.7 billion. The consumer health company’s shares rose about 20% in premarket trading following the deal. Kenvue has endured several challenges since its spinoff from ...
by

Lilly to build $3 billion Dutch plant to boost weight-loss pill production

(Reuters) -Eli Lilly said on Monday it plans to build a new $3 billion manufacturing plant in the Netherlands to expand the production capacity for its keenly watched weight-loss pill, orforglipron, and other oral medicines. The Indianapolis-based drugmaker has shelled out billions of dollars ...
by

Gut microbiome tests are everywhere. Should you get one?

At-home gut microbiome tests are trending, selling insights to the curious, empowerment to the chronically ill and a claimed path to longevity to the wellness-conscious. Private companies are offering tests, costing $100 to $500 or more, that promise a bacterial inventory of your intestines. But can ...
by

UniQure shares plummet as FDA says inadequate clinical data for Huntington’s therapy

(Reuters) -UniQure, said on Monday the U.S. health regulator has deemed clinical data for its gene therapy for Huntington’s disease as inadequate, sending the Dutch company’s U.S.-listed shares plummeting over 68% in premarket trading. The company’s shares had surged nearly 200% in September after reporting ...
First Previous656667686970717273Next Last